ZL-1310 shows promising activity in DLL3-positive neuroendocrine carcinomas

DLL3 expression in circulating tumour cells predicts response to tarlatamab in small cell lung cancer

Oncolytic adenovirus VCN-01 plus chemo shows promising survival benefit in metastatic pancreatic cancer

Trastuzumab and tucatinib enable organ preservation in HER2-positive rectal cancer

Rilvegostomig clears ctDNA and delays recurrence in high-risk head and neck cancer

Setidegrasib shows promising activity in KRAS G12D-mutated advanced NSCLC

mCRPC treatment sequencing: Need for optimal therapy at the earliest opportunity

Development and challenges for T-cell engagers as a novel treatment for lung cancer and mesothelioma

Cemiplimab shows durable 6-year survival benefit in PD-L1 high advanced NSCLC

MK-1084 plus pembrolizumab achieves high response rates in KRAS G12C mutated non-small cell lung cancer

Durvalumab plus chemotherapy improves survival in extensive-stage small cell lung cancer regardless of tumour laterality

Durvalumab improves survival and delays progression in limited-stage small cell lung cancer